Will New Ratings Coverage by Chardan Capital Markets Help Voyager Therapeutics (NASDAQ:VYGR) Stock This Week?

Share

Why Has Chardan Capital Markets Given Voyager Therapeutics (NASDAQ:VYGR) a $20 Price Target

In a note issued to clients and investors on Wednesday, 9 December, Chardan Capital Markets analyst has today have initiated coverage for Voyager Therapeutics (NASDAQ:VYGR) shares with a Sell rating. The price target is now $20.

From a total of 1 analysts covering Voyager Therapeutics (NASDAQ:VYGR) stock, 0 rate it a ”Buy”, 0 a “Sell”, and 0 a ”Hold”. This means that NaN of the ratings are positive. The highest target price is $47 while the lowest target price is $47. The mean of all analyst targets is $47 with a 50.09% above today’s ($27.65) stock price. Voyager Therapeutics was the topic of 3 analyst reports since December 7, 2015 according to the firm StockzIntelligence Inc. Cowen & Co initiated shares on December 7 with “Outperform” rating. Wedbush initiated VYGR stock in a recent report from December 7 with “Outperform” rating.

Approximately 10,425 shares of stock traded hands. Voyager Therapeutics Inc (NASDAQ:VYGR) has risen 6.00% since November 9, 2015 and is uptrending. It has outperformed by 6.80% the S&P500.

Will New Ratings Coverage by Chardan Capital Markets Help Voyager Therapeutics (NASDAQ:VYGR) Stock This Week?

Voyager Therapeutics, Inc. is a clinical-stage gene therapy company. The company has a market cap of $722.14 million. The Firm focuses on developing life-changing treatments for patients suffering from severe diseases of the central nervous system . It currently has negative earnings. The Company’s product engine has generated programs for five CNS indications, including advanced Parkinson’s disease; a monogenic form of amyotrophic lateral sclerosis; Friedreich’s ataxia; Huntington’s disease, and spinal muscular atrophy.

According to Zacks Investment Research, “Voyager Therapeutics, Inc. is a gene therapy company. It focuses on the development of treatments for patients suffering from severe diseases of the central nervous system. Its pipeline includes VY-AADC01, which is in Phase 1b clinical trials for treatment of Parkinson’s disease and preclinical programs comprise VY-SOD101 for a monogenic form of amyotrophic lateral sclerosis, VY-FXN01 for Friedreich ataxia and VY-HTT01 for Huntington’s disease as well as VY-SMN101 for neuromuscular disease. Voyager Therapeutics, Inc. is headquartered in Cambridge, Massachusetts.” Get a free copy of the Zacks research report on Voyager Therapeutics Inc (VYGR).

COMMENTS: